Regulatory Storm Hits Hims & Hers as FDA Targets Marketing Claims

Shares of telehealth provider Hims & Hers Health faced significant pressure this week following a regulatory confrontation with the U.S. Food and Drug Administration. The agency issued a formal warning letter concerning the company’s advertising practices for its compounded weight loss medications, sending the stock downward and raising serious questions about its core business strategy.

Aggressive Marketing Draws Regulatory Scrutiny

The FDA’s communication, dated September 9, took specific issue with how Hims & Hers promoted its semaglutid-based products. These compounded formulations mimic the active ingredient found in branded drugs like Ozempic and Wegovy. Regulators flagged claims such as “same active ingredient as Ozempic and Wegovy” and “clinically proven ingredients” as being “false or misleading.”

The agency delivered an unequivocal message: “Compounded drug products are not FDA-approved.” This statement directly challenges marketing language that implicitly suggested therapeutic equivalence with fully approved pharmaceuticals, a potential violation of U.S. food and drug law.

Part of Broader Regulatory Crackdown

This action against Hims & Hers appears to be part of a wider enforcement initiative. The FDA reportedly dispatched approximately 100 similar warning letters to various pharmaceutical companies, including industry leaders Eli Lilly and Novo Nordisk.

FDA Commissioner Dr. Marty Makary had previously publicly criticized the company’s Super Bowl advertisement, calling it a “violation of FDA regulations” for highlighting benefits while providing insufficient information about potential side effects. The current administration under Health Secretary Robert F. Kennedy Jr. has seemingly prioritized oversight of pharmaceutical marketing, placing telehealth providers—who have often operated in regulatory gray areas—under increased examination.

Business Model Faces Fundamental Challenge

The FDA’s move strikes at the heart of the company’s growth strategy. During the first half of 2025, Hims & Hers generated $420 million in revenue from its weight loss medications while spending $449 million on marketing. Its entire growth narrative has been built upon aggressively promoting affordable alternatives to expensive branded medications.

Should investors sell immediately? Or is it worth buying Hims & Hers?

Established pharmaceutical giants are mounting their own resistance. Novo Nordisk terminated a short-lived collaboration with Hims & Hers back in June, accusing the company of “deceptive advertising.” The addition of formal regulatory action creates a more challenging environment.

The company now has a 15-business-day window to outline corrective measures. Failure to provide a satisfactory response could result in legal action, including potential product seizures and court injunctions.

Strong Performance Metrics Amid Uncertainty

Despite this recent setback, the stock’s performance tells a story of significant investor enthusiasm. Shares have advanced 214% over the past twelve months and are up 94% year-to-date.

The fundamental business metrics remain robust. With 2.4 million subscribers and projected annual revenue between $2.3 and $2.4 billion, the company continues to demonstrate impressive growth.

Analysts at investment bank BTIG have maintained their buy recommendation despite the regulatory overhang, expressing confidence in management’s ability to navigate the current challenges.

Nevertheless, the FDA’s criticism addresses the very foundation of the company’s value proposition. Upcoming quarterly results in November will provide crucial evidence: whether subscribers remain loyal despite regulatory concerns, or whether the FDA’s action will materially impact the company’s growth trajectory.